A Phase 2 interventional study of Fremanezumab and Placebo in Post-Traumatic Headache, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 33 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-12-13.
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Post-Traumatic Headache with a site in United States — 11 open to participants now, 12 under way, none of them phase 3. Post-Traumatic Headache · United States.
Among the 64 studies in Post-Traumatic Headache with a site in United States, this one is the 17th largest by enrollment of the 57 interventional ones that give a count, is one of 5 that started in 2017, is one of 9 in phase 2, and was the 22nd registered.
192 studies on the registry are indexed under Post-Traumatic Headache; 54 are open to participants now.
Browse Post-Traumatic Headache studies →11 of the 64 studies in Post-Traumatic Headache with a site in United States are open now. Recruiting first, the newest first:
Yale University · Sites in United States
Ages 18+
Texas Tech University Health Sciences Center · Sites in United States
Ages 18–65
Northwestern University · Sites in United States
Ages 18+
Alabama Physical Therapy & Acupuncture · Sites in United States
Ages 18–65
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Post-Traumatic Headache studies recruiting now, 5 (17%) set no upper age limit and 24 (80%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 3 · Phase 4 8
First in 2005; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 87 is above the median of 44 across 169 interventional studies indexed under Post-Traumatic Headache.
Median enrollment 36 across the 57 interventional studies, 101 across the 7 observational. Of the 44 that completed or were terminated, 15 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 64 have an industry lead sponsor. The 10 most frequent:
This study is registered under Teva Branded Pharmaceutical Products R&D, Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Branded Pharmaceutical Products R&D, Inc. is the lead sponsor of 206 studies on the registry; none are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 47 (96%) have results posted.
Teva Pharmaceutical Industries, Ltd. has 1 study filed under Post-Traumatic Headache — fewer than ten, so there is no comparison to draw.
6 of the studies in Post-Traumatic Headache with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05414708Walter Reed National Military Medical CenterArt Therapy and Emotional Well Being in Military Populations With Posttraumatic Stress Symptoms | 2026-12 |
| NCT07309874Texas Tech University Health Sciences CenterEffect of Ultrasound-Guided Dry Needling Targeting Rectus Capitus Posterior Major on Individuals With Headaches | 2026-12-01 |
| NCT07624279American Society of Pain and Neuroscience, Inc.nVNS, CBD, and SoC for Persistent Post-Traumatic Headache | 2027-07-31 |
| NCT05491915SPR Therapeutics, Inc.The MONARCH Case Series Study: SPRINT® Peripheral Nerve Stimulation for the Treatment of Head Pain | 2027-08 |
| NCT05620719The University of Texas Health Science Center at San AntonioMultisite Advancement of Research on Chronic Posttraumatic Headache | 2027-09 |
Add all 6 to your calendar (.ics) → With an account.
Among the 64 studies in Post-Traumatic Headache with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of fremanezumab in adult participants aged 18 to 70 years, inclusive, for the prevention of PTH. The study will include a double-blind (DB) treatment period (12 weeks) and an open-label (OL) treatment period (12 weeks).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
NOTE- Additional criteria apply, please contact the investigator for more information.
Exclusion Criteria:
NOTE- Additional criteria apply, please contact the investigator for more information.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive fremanezumab 675 milligrams (mg) administered as 3 subcutaneous (SC) injections (225 mg/1.5 milliliters \[mL\] each) at randomization (Week 0), Weeks 4, and 8 during the DB treatment period. Participants who complete the DB treatment period and continue into the OL treatment period will receive fremanezumab 675 mg administered as 3 SC injections (225 mg/1.5 mL each) at Weeks 12, 16, and 20 during the OL treatment period.
Drug: Fremanezumab
Participants will receive placebo matching to fremanezumab administered as 3 SC injections (1.5 mL each) at randomization (Week 0), Weeks 4, and 8 during the DB treatment period. Participants who complete the DB treatment period and continue into the OL treatment period will receive fremanezumab 675 mg administered as 3 SC injections (225 mg/1.5 mL each) at Weeks 12, 16, and 20 during the OL treatment period.
Drug: Placebo
Fremanezumab will be administered per dose and schedule specified in the arm.
Also known as: TEV-48125
Placebo matching to fremanezumab will be administered per schedule specified in the arm.
DB Period: Mean Change From Baseline in Monthly Average Number of Headache Days of at Least Moderate Severity During the 12-Week Treatment Period After the First Dose of Fremanezumab
A headache day was defined as a day when a participant reported a headache of at least moderate severity. Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \* 28. The change was calculated as post-baseline value - baseline value. Least square (LS) mean was calculated using analysis of covariance (ANCOVA) model with the duration of post traumatic headache history (less than 12 month since the brain injury or greater or equal to 12 month since the brain injury) and treatment as fixed effects and the baseline monthly average number of headache days of at least moderate severity as a covariate.
Time frame: Baseline (Day -28 to Day -1), up to Week 12
DB Period: Number of Participants Reaching at Least 50% Reduction From Baseline in Monthly Average Number of Headache Days of Any Severity During 12-Week Treatment With Fremanezumab
Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \* 28.
Time frame: Baseline (Day -28 to Day-1) up to Week 12
DB Period: Number of Participants Reaching at Least 50% Reduction From Baseline in the Monthly Average Number of Headache Days of at Least Moderate Severity During 12-Week Treatment With Fremanezumab
A headache day was defined as a day when a participant reported a headache of at least moderate severity. Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \* 28.
Time frame: Baseline (Day -28 to Day-1) up to Week 12
DB Period: Number of Participants Reaching at Least 50% Reduction From Baseline in the Monthly Average Number of Headache Days of at Least Moderate Severity During First 4-Week (Month 1), 5- to 8-Week (Month 2), and 9- to 12-Week (Month 3)
A headache day was defined as a day when a participant reported a headache of at least moderate severity. Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \* 28.
Time frame: Baseline (Day -28 to Day-1) up to Months 1, 2, and 3
DB Period: Change From Baseline in the Number of Headache Days of At Least Moderate Severity During the First 4-Week (Month 1), 5- to 8-Week (Month 2), and 9- to 12-Week (Month 3)
A headache day was defined as a day when a participant reported a headache of at least moderate severity. Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \* 28. The change was calculated as post-baseline value - baseline value. LS mean was calculated using ANCOVA model with the duration of post traumatic headache history (less than 12 month since the brain injury or greater or equal to 12 month since the brain injury) and treatment as fixed effects and the baseline monthly average number of headache days of at least moderate severity as a covariate. This approach was used in generating the LS mean values only and was not considered to be an additional statistical analysis, no additional statistical analyses are reported for this outcome measure.
Time frame: Baseline (Day -28 to Day -1), up to Months 1, 2, and 3
DB Period: Change From Baseline in Disability Score, as Measured by the 6-Item Headache Impact Test (HIT-6) Total Score at Week 12 After the First Dose of Fremanezumab
HIT-6 is a tool used to measure the impact headaches have on a participant's normal daily life and ability to function. The HIT-6 consists of 6 items, including pain, social functioning, role functioning, vitality, cognitive functioning, and psychological distress. Each item was answered on a 5-point Likert scale (6=never, 8=rarely, 10=sometimes, 11=very often, or 13=always), which were summed to produce a total score that ranged from 36 to 78, with larger scores reflecting greater impact of headache on the daily life of the participant.
Time frame: Baseline (Day -28 to Day -1), Week 12
DB Period: Number of Participants (Responder and Non-Responder) With the Patient Global Impression of Change (PGIC) Scale at Weeks 4, 8, and 12 After the First Dose of Fremanezumab
The PGIC scale is a validated generic tool for the assessment of overall change in the severity of illness following treatment. Participants rated how they felt during assigned time points compared with how they felt before receiving study drug on a 7-point scale, where 1 = No change (or it got worse); 2 = Almost the same, hardly any change at all; 3 = A little better, but no noticeable change; 4 = Somewhat better, but the change has not made any real difference; 5 = Moderately better, and a slight but noticeable change; 6 = Better, and a definite improvement that has made a real and worthwhile difference; and 7 = A great deal better, and a considerable improvement that has made all the difference. Responders were those with a scale of 5 to 7 and non-responders were those with a scale of 1 to 4.
Time frame: Weeks 4, 8, and 12
DB Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were defined as AEs occurring at or after the first dose of the study drug. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Time frame: Baseline (Day -28 to -1) up to Week 12
OL Period: Number of Participants With TEAEs
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were defined as AEs occurring at or after the first dose of the study drug. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Time frame: Week 12 up to Week 24
DB Period: Number of Participants Who Did Not Complete the Study
Number of participants who did not complete the study due to any reason and due to AEs are reported.
Time frame: Baseline (Day -28 to Day -1) up to Week 12
OL Period: Number of Participants Who Did Not Complete the Study
Number of participants who did not complete the study due to any reason and due to AEs are reported.
Time frame: Week 12 up to Week 24
DB Period: Number of Participants Who Received Concomitant Medications
Concomitant medications included: agents acting on renin-angiotensin system, analgesics, anesthetics, anti-parkinson drugs, antianemic preparations, antibacterials for systemic use, antidiarrheals, intestinal antiinflammatory/antiinfective agents, antiemetics and antinauseants, antiepileptics, antifungals for dermatologiocal use, antihistamines for systemic use, antihypertensives, antiinflammatory and antirheumatics, antineoplastic agents, antiobesity preparations, antipruritics, antithrombotics, antivirals for systemic use, beta blocking agents, calcium channel blockers, cardiac therapy, corticosteroids, cough and cold preparations, diuretics, lipid modifying agents, nasal preparations, thyroid therapy, urologicals, vaccines, psycholeptics, psycoanaleptics, ophthalmologicals, general nutrients, mineral supplements, muscle relaxants, vitamins, drugs used in diabetes, sex hormones and modulators of the genital system, immunosuppresants, drugs for acid related disorders etc.
Time frame: Baseline (Day -28 to Day -1) up to Week 12
OL Period: Number of Participants Who Received Concomitant Medications
Concomitant medications included: agents acting on renin-angiotensin system, analgesics, anti-parkinson drugs, antianemic preparations, antibacterials for systemic use, antiemetics and antinauseants, antihistamines for systemic use, antihypertensives, antiinflammatory and antirheumatics, antineoplastic agents, antithrombotics, beta blocking agents, calcium channel blockers, corticosteroids for systemic use, cough and cold preparations, diuretics, lipid modifying agents, nasal preparations, other gynecologicals, other nervous system drugs, thyroid therapy, unspecified herbal and traditional medicine, urologicals, vaccines, psycholeptics, psycoanaleptics, general nutrients, mineral supplements, muscle relaxants, vitamins, sex hormones and modulators of the genital system, drugs for acid related disorders, drugs for constipation, drugs for obstructive airways disease etc.
Time frame: Week 12 up to Week 24
Number of Participants With Positive Findings on Electronic Columbia Suicide Severity Rating Scale (eC-SSRS)
eC-SSRS is a questionnaire to assess suicidal ideation (severity and intensity) and behavior. Suicidal ideation: A series of 1 -5 questions (with 'yes' or 'no' response) with 5 types of ideation of increasing severity: 1. wish to be dead, 2. non-specific active suicidal thoughts, 3. active suicidal ideation with any methods (not plan) without intent to act, 4. active suicidal ideation with some intent to act, without specific plan, 5. active suicidal ideation with specific plan and intent. A positive finding was defined as a 'yes' response to question 4 or 5.
Time frame: Baseline (Day -28 to Day -1) up to Week 24
Number of Participants With Treatment-Emergent Antidrug Antibodies (ADA)
Number of participants with treatment-emergent antidrug antibodies reported.
Time frame: Baseline (Day -28 to Day -1) up to Week 24
| Milestone | Fremanezumab | Placebo |
|---|---|---|
| Started | 44 | 43 |
| Received at least 1 dose of study drug | 43 | 43 |
| Full analysis set (fas) | 42 | 43 |
| Completed | 29 | 26 |
| Not completed | 15 | 17 |
| Withdrew: Protocol violation | 2 | 2 |
| Withdrew: Withdrawal by subject | 4 | 8 |
| Withdrew: Lost to follow-up | 7 | 4 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Other than specified | 1 | 2 |
| Milestone | Fremanezumab | Placebo |
|---|---|---|
| Started | 35 | 35 |
| Entered in ol period for anti-drug antibody (ada) only | 26 | 28 |
| Received at least 1 dose of study drug | 9 | 7 |
| Completed | 8 | 6 |
| Not completed | 27 | 29 |
| Withdrew: Entered for ada assessment only, not treated | 26 | 28 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Other than specified | 0 | 1 |
A headache day was defined as a day when a participant reported a headache of at least moderate severity. Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \* 28. The change was calculated as post-baseline value - baseline value. Least square (LS) mean was calculated using analysis of covariance (ANCOVA) model with the duration of post traumatic headache history (less than 12 month since the brain injury or greater or equal to 12 month since the brain injury) and treatment as fixed effects and the baseline monthly average number of headache days of at least moderate severity as a covariate.
| days | Fremanezumab | Placebo |
|---|---|---|
| DB Period: Mean Change From Baseline in Monthly Average Number of Headache Days of at Least Moderate Severity During the 12-Week Treatment Period After the First Dose of Fremanezumab | -3.6 ± 0.99 | -5.1 ± 1.01 |
Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \* 28.
| Participants | Fremanezumab | Placebo |
|---|---|---|
| DB Period: Number of Participants Reaching at Least 50% Reduction From Baseline in Monthly Average Number of Headache Days of Any Severity During 12-Week Treatment With Fremanezumab | 5 | 4 |
A headache day was defined as a day when a participant reported a headache of at least moderate severity. Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \* 28.
| Participants | Fremanezumab | Placebo |
|---|---|---|
| DB Period: Number of Participants Reaching at Least 50% Reduction From Baseline in the Monthly Average Number of Headache Days of at Least Moderate Severity During 12-Week Treatment With Fremanezumab | 9 | 11 |
A headache day was defined as a day when a participant reported a headache of at least moderate severity. Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \* 28.
| Participants | Fremanezumab | Placebo |
|---|---|---|
| Month 1 | 8 | 11 |
| Month 2 | 8 | 14 |
| Month 3 | 14 | 12 |
A headache day was defined as a day when a participant reported a headache of at least moderate severity. Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \* 28. The change was calculated as post-baseline value - baseline value. LS mean was calculated using ANCOVA model with the duration of post traumatic headache history (less than 12 month since the brain injury or greater or equal to 12 month since the brain injury) and treatment as fixed effects and the baseline monthly average number of headache days of at least moderate severity as a covariate. This approach was used in generating the LS mean values only and was not considered to be an additional statistical analysis, no additional statistical analyses are reported for this outcome measure.
| days | Fremanezumab | Placebo |
|---|---|---|
| Change at Month 1 | -3.6 ± 0.97 | -4.0 ± 0.99 |
| Change at Month 2 | -3.7 ± 1.06 | -6.7 ± 1.06 |
| Change at Month 3 | -5.2 ± 1.20 | -7.2 ± 1.21 |
HIT-6 is a tool used to measure the impact headaches have on a participant's normal daily life and ability to function. The HIT-6 consists of 6 items, including pain, social functioning, role functioning, vitality, cognitive functioning, and psychological distress. Each item was answered on a 5-point Likert scale (6=never, 8=rarely, 10=sometimes, 11=very often, or 13=always), which were summed to produce a total score that ranged from 36 to 78, with larger scores reflecting greater impact of headache on the daily life of the participant.
| units on a scale | Fremanezumab | Placebo |
|---|---|---|
| DB Period: Change From Baseline in Disability Score, as Measured by the 6-Item Headache Impact Test (HIT-6) Total Score at Week 12 After the First Dose of Fremanezumab | -6.9 ± 4.54 | -10.8 ± 4.65 |
The PGIC scale is a validated generic tool for the assessment of overall change in the severity of illness following treatment. Participants rated how they felt during assigned time points compared with how they felt before receiving study drug on a 7-point scale, where 1 = No change (or it got worse); 2 = Almost the same, hardly any change at all; 3 = A little better, but no noticeable change; 4 = Somewhat better, but the change has not made any real difference; 5 = Moderately better, and a slight but noticeable change; 6 = Better, and a definite improvement that has made a real and worthwhile difference; and 7 = A great deal better, and a considerable improvement that has made all the difference. Responders were those with a scale of 5 to 7 and non-responders were those with a scale of 1 to 4.
| Participants | Fremanezumab | Placebo |
|---|---|---|
| Week 4 — Responder | 12 | 11 |
| Week 4 — Non-Responder | 24 | 26 |
| Week 4 — Missing | 6 | 6 |
| Week 8 — Responder | 14 | 17 |
| Week 8 — Non-Responder | 20 | 21 |
| Week 8 — Missing | 8 | 5 |
| Week 12 — Responder | 11 | 16 |
| Week 12 — Non-Responder | 20 | 16 |
| Week 12 — Missing | 11 | 11 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were defined as AEs occurring at or after the first dose of the study drug. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
| Participants | Fremanezumab | Placebo |
|---|---|---|
| DB Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 31 | 35 |
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were defined as AEs occurring at or after the first dose of the study drug. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
| Participants | Fremanezumab | Placebo |
|---|---|---|
| OL Period: Number of Participants With TEAEs | 8 | 6 |
Number of participants who did not complete the study due to any reason and due to AEs are reported.
| Participants | Fremanezumab | Placebo |
|---|---|---|
| Discontinued study due to any reason | 15 | 17 |
| Discontinued study due to AEs | 1 | 1 |
Number of participants who did not complete the study due to any reason and due to AEs are reported.
| Participants | Fremanezumab | Placebo |
|---|---|---|
| Discontinued study due to any reason | 1 | 1 |
| Discontinued study due to AEs | 0 | 0 |
Concomitant medications included: agents acting on renin-angiotensin system, analgesics, anesthetics, anti-parkinson drugs, antianemic preparations, antibacterials for systemic use, antidiarrheals, intestinal antiinflammatory/antiinfective agents, antiemetics and antinauseants, antiepileptics, antifungals for dermatologiocal use, antihistamines for systemic use, antihypertensives, antiinflammatory and antirheumatics, antineoplastic agents, antiobesity preparations, antipruritics, antithrombotics, antivirals for systemic use, beta blocking agents, calcium channel blockers, cardiac therapy, corticosteroids, cough and cold preparations, diuretics, lipid modifying agents, nasal preparations, thyroid therapy, urologicals, vaccines, psycholeptics, psycoanaleptics, ophthalmologicals, general nutrients, mineral supplements, muscle relaxants, vitamins, drugs used in diabetes, sex hormones and modulators of the genital system, immunosuppresants, drugs for acid related disorders etc.
| Participants | Fremanezumab | Placebo |
|---|---|---|
| DB Period: Number of Participants Who Received Concomitant Medications | 43 | 42 |
Concomitant medications included: agents acting on renin-angiotensin system, analgesics, anti-parkinson drugs, antianemic preparations, antibacterials for systemic use, antiemetics and antinauseants, antihistamines for systemic use, antihypertensives, antiinflammatory and antirheumatics, antineoplastic agents, antithrombotics, beta blocking agents, calcium channel blockers, corticosteroids for systemic use, cough and cold preparations, diuretics, lipid modifying agents, nasal preparations, other gynecologicals, other nervous system drugs, thyroid therapy, unspecified herbal and traditional medicine, urologicals, vaccines, psycholeptics, psycoanaleptics, general nutrients, mineral supplements, muscle relaxants, vitamins, sex hormones and modulators of the genital system, drugs for acid related disorders, drugs for constipation, drugs for obstructive airways disease etc.
| Participants | Fremanezumab | Placebo |
|---|---|---|
| OL Period: Number of Participants Who Received Concomitant Medications | 9 | 7 |
eC-SSRS is a questionnaire to assess suicidal ideation (severity and intensity) and behavior. Suicidal ideation: A series of 1 -5 questions (with 'yes' or 'no' response) with 5 types of ideation of increasing severity: 1. wish to be dead, 2. non-specific active suicidal thoughts, 3. active suicidal ideation with any methods (not plan) without intent to act, 4. active suicidal ideation with some intent to act, without specific plan, 5. active suicidal ideation with specific plan and intent. A positive finding was defined as a 'yes' response to question 4 or 5.
| Participants | Fremanezumab | Placebo |
|---|---|---|
| Number of Participants With Positive Findings on Electronic Columbia Suicide Severity Rating Scale (eC-SSRS) | 0 | 0 |
Number of participants with treatment-emergent antidrug antibodies reported.
| Participants | Fremanezumab | Placebo |
|---|---|---|
| Number of Participants With Treatment-Emergent Antidrug Antibodies (ADA) | 0 | 0 |
Collected over Baseline (Day -28 to Day -1) up to Week 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fremanezumab | 0/43 (0%) | 2/43 (4.7%) | 28/43 (65.1%) |
| Placebo | 0/43 (0%) | 1/43 (2.3%) | 29/43 (67.4%) |
| Event | Fremanezumab | Placebo |
|---|---|---|
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/43 | 0/43 |
| Non-cardiac chest painGeneral disorders | 0/43 | 1/43 |
| CholelithiasisHepatobiliary disorders | 0/43 | 1/43 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/43 | 0/43 |
| HypotensionVascular disorders | 1/43 | 0/43 |
| Event | Fremanezumab | Placebo |
|---|---|---|
| Injection site indurationGeneral disorders | 18/43 | 14/43 |
| Injection site painGeneral disorders | 14/43 | 15/43 |
| Injection site erythemaGeneral disorders | 11/43 | 14/43 |
| HeadacheNervous system disorders | 6/43 | 2/43 |
| Upper respiratory tract infectionInfections and infestations | 1/43 | 5/43 |
| NauseaGastrointestinal disorders | 4/43 | 2/43 |
| Injection site pruritusGeneral disorders | 4/43 | 2/43 |
| NasopharyngitisInfections and infestations | 2/43 | 4/43 |
| SinusitisInfections and infestations | 4/43 | 3/43 |
| International normalised ratio increasedInvestigations | 4/43 | 1/43 |
Intent-to-treat (ITT) analysis set included all randomized participants.
| Age, Continuous(years) | Fremanezumab | Placebo | Total |
|---|---|---|---|
| Mean | 42.6 ± 13.01 | 43.8 ± 14.48 | 43.2 ± 13.68 |
| Sex: Female, Male(Participants) | Fremanezumab | Placebo | Total |
|---|---|---|---|
| Female | 25 | 25 | 50 |
| Male | 19 | 18 | 37 |
| Ethnicity (NIH/OMB)(Participants) | Fremanezumab | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 4 | 8 |
| Not Hispanic or Latino | 40 | 38 | 78 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Fremanezumab | Placebo | Total |
|---|---|---|---|
| Race — White | 41 | 39 | 80 |
| Race — Black or African American | 3 | 1 | 4 |
| Race — Native Hawaiian or other Pacific Islander | 0 | 1 | 1 |
| Race — Other | 0 | 2 | 2 |
| Number of Headache Days of at Least Moderate Severity(days) | Fremanezumab | Placebo | Total |
|---|---|---|---|
| Mean | 18.7 ± 7.03 | 18.5 ± 6.12 | 18.6 ± 6.56 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2017 to primary completion in Mar 2020, 26 months.
Results were first posted in Mar 2021, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fremanezumab
Teva Branded Pharmaceutical Products R&D, Inc. →